Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Talk:4C-D

From PsychonautWiki Archive
Revision as of 02:23, 26 July 2020 by >Dextromethorphan (Grammatics)
Jump to navigation Jump to search
Summary sheet: 4C-D
4C-D
Chemical Nomenclature
Common names 4C-D, ARIADNE, dimoxamine, α-ethyl-2C-D, α-ethyl-DOM, BL-3912
Substitutive name 4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)butan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenisobutylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 10 mg
Light 10 - 30 mg
Common 30 - 60 mg
Strong 60 - 100 mg
Heavy 100 mg +
Duration
Total 4 - 10 hours
Onset 20 - 45 minutes
Come up 30 - 60 minutes
Peak 1.5 - 4.5 hours
Offset 1.5 - 4 hours
After effects 1 - 8 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine (also known as ARIADNE, dimoxamine BL-3912 and more commonly as 4C-D) is a synthetic psychedelic that produces a mixture of psychedelic, entactogenic and stimulant effects when administered.

4C-D was first synthesized by Alexander Shulgin and documented in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved"). Shulgin has researched dosages up to 32 milligrams although anecdotal reports suggest that the dosage for 4C-D is generally higher than what Shulgin documented. Shulgin describes 4C-D as not a true psychedelic and it possessing anti-depressant effects. It has been researched as a potential therapeutic agent due to its mood-lifting effects

4C-D has been scarcely distributed as a gray area research chemical by online vendors. Many anecdotal reports suggest that the psychedelic effects begin to unfold at the higher dose range. The dosage levels of 4C-D are therefore not fully clear and one should start at a lower dose when researching this compound. It is highly advised to use harm reduction practices if using this substance.

Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential nootropic, albeit with mixed results.[1]

Today, 2C-D is used both recreationally and as an entheogen. It is rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.

History and culture

4C-D was once patented as a therapeutic aid in elderly people.

Chemistry

Generic structure of a phenethylamine molecule

2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring.

2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.

4C-D is the alpha-ethyl analog of 2C-D and DOM.

Pharmacology

Further information: Serotonergic psychedelic

2C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The head space of 4C-D

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Multi-sensory effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage.

Anecdotal evidence from those within the community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.[3]
  • Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[4]
  • Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[5]
  • China: 2C-D is a controlled substance in China as of October 2015.[6]
  • Denmark: 2C-D is added to the list of Schedule B controlled substances.[7]
  • Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014.[8][9] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[10]
  • Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.[11]
  • Latvia: 2C-D is a Schedule I controlled substance.[12]
  • Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.[13]
  • Switzerland: 2C-D is a controlled substance specifically named under Verzeichnis E.[14]
  • United Kingdom: 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[15]
  • United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.[16]

See also

Forums

References

  1. Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml
  2. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  3. New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf
  4. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  5. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  6. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  7. Bekendtgørelse om euforiserende stoffer | https://www.retsinformation.dk/Forms/R0710.aspx?id=137169
  8. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in Deutsch). Bundesanzeiger Verlag. Retrieved December 10, 2019. 
  9. "Anlage I BtMG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  10. "§ 29 BtMG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  11. Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
  12. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  13. Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  14. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  15. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made
  16. S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text